CL vs ZYME · P/E 34, rev $20.38B vs rev $76.3M
Colgate-Palmolive Company (CL) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported CL revenue for 2025-12-31 was $20.38B. Net income was $2.13B. Revenue was up 1.4% from 2024-12-31 to 2025-12-31. CL currently screens at market cap $70.88B and trailing P/E 34.3.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
CL currently screens at market cap $70.88B and trailing P/E 34.3. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the CL and ZYME stock pages for the full models.
Not investment advice.